http://orcid.org/0000-0002-6765-8830
References
- Tavakolpour S. Current and future treatment options for pemphigus: is it time to move towards more effective treatments? Int Immunopharmacol. 2017;53:133–142.
- Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet (London, England). 2017;389:2031–2040.
- Daneshpazhooh M, Balighi K, Mahmoudi H, et al. Iranian guideline for rituximab therapy in pemphigus patients. Dermatol Ther. 2019;32:e13016.
- Mahmoudi H, Balighi K, Tavakolpour S, et al. Unexpected worsening of pemphigus vulgaris after rituximab: a report of three cases. Int Immunopharmacol. 2019;71:40–42.
- Lykken JM, Candando KM, Tedder TF. Regulatory B10 cell development and function. Int Immunol. 2015;27:471–477.
- Feldman RJ. Paradoxical worsening of pemphigus vulgaris following rituximab therapy. Br J Dermatol. 2015;173:858–859.
- Cohen RZ, Schoen BT, Kugathasan S, et al. Management of anti-drug antibodies to biologic medications in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;69:551–556.
- Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol. 2014;10:612–627.
- Kaegi C, Wuest B, Schreiner J, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019;10:1990.
- Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–138.
- Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411–419.
- Declerck P, Danesi R, Petersel D, et al. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77:671–677.